Abstract: Filaments that contain a filament-forming material and an additive, nonwoven webs, and methods for making such filaments are provided.

Abstract: A computer-implemented method includes receiving a request for one of a network session and a virtual network function, wherein the request includes a single packet authorization request. The method further includes classifying the single packet authorization request at a first service classifier. The method further includes routing the request, via a service function forwarder, to a single packet authorization service function for validation. The method further includes instantiating a security virtual function in response to the request, wherein instantiating the security virtual function occurs after validation of the single packet authorization request. The method further includes configuring the security virtual function to apply at least one connection policy to allow or deny traffic in a data session. The method further includes, in response to allowing the data session, terminating the security virtual function after the data session has concluded.

Abstract: Embodiments are directed to monitoring network traffic using network monitoring computers (NMCs). Metrics may be determined based on monitoring network traffic associated with a plurality of entities each associated with a profile that includes the metrics for each entity. Beaconing metrics associated with beaconing activity may be determined based on the metrics. The profile of each entity may be compared with the beaconing metrics to determine the entities that may be engaged in beaconing activity. The entities may be characterized based on beaconing activity such that the beaconing activity includes communication with endpoints associated with the third parties, employing communication protocols associated with the third-parties, or exchanging payloads consistent with the beaconing activity. Reports that include information associated with the entities and its beaconing activity may be generated.

Abstract: In one aspect of the disclosure, a method includes rendering, by a processor, a virtual environment associating, by the processor, exercise machine control signals with the virtual environment, and displaying, by the processor, the virtual environment on a video wall. The method may include receiving, by the processor, a video of a trainer on an exercise machine in front of the video wall displaying the virtual environment, wherein the exercise machine has one or more parameters which are controlled according to the exercise machine control signals associated with the virtual environment, associating, by the processor, the control signals with the video of the trainer in the virtual environment, and publishing the video with the associated control signals for use on a remote exercise machine.

Abstract: Filaments that contain a filament-forming material and an additive, nonwoven webs, and methods for making such filaments are provided.

Abstract: Processing an ingress packet in a packet pipeline to determine a forwarding rule includes identifying a matching rule in each forwarding table in the pipeline. Prefix lengths of the respective matching rules are compared. The matching rule with the greatest prefix length serves as the basis for forwarding an egress packet.

Abstract: A method for performing downhole gas lift operations includes coupling a gas lift valve to a tubing, wherein the gas lift valve includes an actuator, a flow control device disposed in the actuator, and a closure member that is initially in an open position; injecting a gas downhole and exterior to the tubing; urging the gas to enter the tubing via the gas lift valve; and creating a sufficient pressure differential across the gas lift valve to move the actuator, thereby causing the closure member to close the gas lift valve.

Abstract: Novel lipid-nucleic acid particulate complexes which are useful for in vitro or in vivo gene transfer are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the lipid-nucleic acid complexes form particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.

Abstract: Novel lipid-nucleic acid particulate complexes which are useful for in vitro or in vivo gene transfer are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the lipid-nucleic acid complexes form particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.

Abstract: The present invention includes novel liposomes comprising dihydrosphingomyelin. The invention also includes compositions comprising these liposomes and a therapeutic agent, in addition to methods and kits for delivering a therapeutic agent or treating a disease, e.g., a cancer, using these compositions.

Abstract: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.

Abstract: Lipid-nucleic acid particles can provide therapeutic benefits, even when the nucleic acid is not complementary to coding sequences in target cells. It has been found that lipid-nucleic acid particles, including those containing non-sequence specific oligodeoxynucleotides, can be used to stimulate cytokine secretion, thus enhancing the overall immune response of a treated mammal. Further, immune response to specific target antigens can be induced by administration of a antigenic molecule in association with lipid particles containing non-sequence specific oligodeoxynucleotides. The nucleic acid which is included in the lipid-nucleic acid particle can be a phosphodiester (i.e.

Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.

Abstract: Particle aggregation of lipid:nucleic acid complex particles is prevented by incorporating a non-cationic lipid into lipid:nucleic acid complex particles containing a cationic lipid and a nucleic acid polymer. The non-cationic lipid is a polyethylene glycol-based polymer.

Abstract: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.

Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.

Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.

Abstract: Novel lipid-nucleic acid particulate complexes which are useful for in vitro or in vivo gene transfer are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the lipid-nucleic acid complexes form particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.

Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.

Abstract: Particle aggregation of lipid:nucleic acid complex particles is prevented by incorporating a non-cationic lipid into lipid:nucleic acid complex particles containing a cationic lipid and a nucleic acid polymer. The non-cationic lipid is a polyethylene glycol-based polymer.